

PORTFOLIO FEATURES

Inception	9 February 2005
Benchmark Index	S&P/ASX300 Accumulation Index
No of holdings	33 (Maximum 35)
Quest AUM	\$894m
Strategy AUM	\$95m
Investment horizon	3 - 5 years
Investment Strategy	Fundamental with a focus on business quality and free cash flow
Derivatives/Shorting	Nil
AFSL	279207
Lonsec Rating	Reviewed and Rated by Lonsec

CONCENTRATED PORTFOLIO MARCH 2026

Global markets were belted as Trump decided the US should attack Iran. The Australian market (XKOA1) fell -7.3% in March, the worst monthly return since 2022, as the conflict and closure of the Strait of Hormuz drove a violent oil price spike, raising inflation and bond yields. This was compounded by a second RBA rate hike. A year ago, Trump roiled markets with his tariff shock; the geopolitical stakes this time are higher, with cascading effects across energy security, supply chains and global growth. The month was as chaotic as any in recent memory. Markets whipsawed on near-daily developments as Trump alternated between threatening the end of Iran entirely, plans to seize the Strait and claiming victory. A market anxious about AI disruption and cracks in private credit was poorly positioned to absorb a stagflationary oil shock.

All markets reacted badly: **S&P 500** -5.1%, **UK** -6.7%, **Germany** -10.3%, **Japan** -13.2%. Government 10-year yields jumped reflecting the uncertainty and stagflation risks, adding further pressure to long duration valuations.

Large caps materially outperformed mid and small caps. Energy stocks surged +19% as Brent +43%, WTI +51% and JKM LNG +88% soared. While dramatic, energy stock moves were well below oil given the challenge estimating duration of this conflict. **InfoTech** -13%, **REITs** -11% and **Discretionary** -9% were hardest hit outside of **Gold** -23% which was the worst sector. Gold stocks fell far more than the metal itself (-11%) given the dual headwinds of a stronger USD / higher interest and following their extraordinary run.

The Quest portfolio returned -10.5%, underperforming the benchmark. Two factors dominated: energy underweight and **Immutep** clinical trial failure, accounting for 60% of the underperformance. Other detractors included **Judo**, **ALS** and **360**. Our five largest overweight positions collectively added value given strength in **Origin**, **Infratil** and modest outperformance of **Aristocrat** and **Challenger**.

Immutep fell -88% after its global TACTI-004 Phase III trial was halted on risk/benefit grounds. Failure of this futility hurdle was a shocking outcome. Safety concerns appear to be a factor. Until now, the drug Efti had a fifteen-year safety record across eleven trials and over 650 patients. Despite the modest position we carried binary risk here and paid the price.

The portfolio is positioned for a de-escalation in the middle east, with a ceasefire in everyone's interests and the clock ticking until the US mid term elections.

STOCK PERFORMANCE MARCH 2026

POSITIVE	
PLS Group	+21%
Commonwealth Bank	+18%
Ramsay Health Care	+18%
BHP	+15%
National Aust Bank	+13%
NEGATIVE	
Immutep	-88%
Capricorn Metals	-25%
Emerald Resources	-24%
Life 360	-24%
Judo Capital	-22%

Performance*	1 month	3 months	1 year	3yrs (pa)	5yrs (pa)	10 yrs (pa)	15yrs (pa)	Since inception (pa)
To 31 March 2026								
Quest Aust Equities Concentrated	-10.7%	-9.7%	0.1%	2.9%	5.9%	10.1%	9.8%	10.5%
ASX300 Accumulation index	-7.3%	-2.0%	11.6%	9.4%	8.5%	9.4%	8.1%	7.8%
Value added	-3.4%	-7.7%	-11.5%	-6.5%	-2.6%	0.7%	1.7%	2.7%

*Returns before fees and tax based on the JBWere platform model portfolio. **Past performance is no guarantee of future performance.** Individual returns will differ for investors, depending on when the initial investment was established and the timing of any additional investments or redemptions. Inception date is February 2005




PORTFOLIO ACTIVITY

Gold behaved more like a risk asset than a haven, falling 12% in USD terms despite the escalating Middle East conflict. The sell-off was driven by record gold related ETF outflows of US\$13 billion as leveraged investors and CTAs liquidated to meet margin calls amid a surging US dollar and rising real yields. Emerging market central banks added to selling pressure, mobilising reserves to defend weakening currencies. The AUD gold price declined roughly 10%, yet ASX gold equities sold off far more severely at 25–40%. The structural bull case remains firmly intact. US fiscal deficits show no sign of narrowing, with the \$USD's share of global central bank reserves at its lowest since 1994 (~58%) while gold's share continues to rise. Central bank buying is broadening and geopolitical risk has intensified. Quest used the correction to increase exposure.

Quest’s December 2025 quarterly review highlighted 2026 as the point applied AI would begin to meaningfully reshape labour markets. That inflection is now visible, with major technology companies (including Meta, Wisetech and Block) undertaking material headcount reductions as AI capabilities substitute for human tasks. This constitutes a multi-year structural headwind for global employment and earnings visibility. Most analysis suggests routine, rules-based roles (such as clerical and data processing functions) are materially more exposed than skilled, site-based trades like electricians. The chart below is one estimate with 50% of Australian jobs in the not exposed (left) categories. The scale and timing of disruption will partly hinge on the adoption of robotics and autonomous vehicles, as well as how quickly regulatory/legal frameworks adapt. Over previous months we have positioned the portfolio to benefit from the rollout of AI with holdings in data centre suppliers **Infratil** and **Goodman**, as well as exited businesses exposed to AI disruption. We have added **Dexus** to the latter list as AI-driven disruption has pushed out our expectations of improvement in the office market.

CHART OF THE MONTH

Figure 4 - Automation & AI risk scores across 470 occupation groups



Source: ABS, ILO, Macquarie Research, March 2026

Bubble sizing based on the Australian workforce in November 2025

INVESTMENT PROFILE

The Quest Australian Equities Concentrated Portfolio is a Separately Managed Account (SMA), actively managed by Quest Asset Partners Pty Limited. Our objective is to outperform the S&P/ASX300 Accumulation Index. The SMA structure allows the investor to retain beneficial ownership of the portfolio while maximising transactional and tax visibility.

CONTACT THE MANAGERS

Michael Evans ph.02 9409 2300
mevans@questap.com.au

Troy Cairns ph.02 9409 2303
tcairns@questap.com.au

Swapnan Pandya ph.02 9409 2302
spandya@questap.com.au

Disclaimer

This report has been prepared by Quest Asset Partners Pty Limited, AFSL 279207 (wholesale), ABN 47 109 448 802. It should be regarded as general information only rather than advice. It has been prepared without taking into account any person's objectives, financial situation or needs. Whilst Quest has used its best endeavours to ensure the information within this document is accurate it cannot be relied upon in any way and recipients must make their own enquiries concerning the accuracy of the information within. Past performance is not a reliable indicator of future performance. All performance figures are based on the JBWere Multi-Asset platform seed portfolio. Performance can vary by platform and client due to mandate restrictions and other constraints. Before making any financial investment decisions we recommend recipients obtain legal and taxation advice appropriate to their particular needs. Investment in a Quest Asset Partners Separately Managed Account can only be made on completion of all the required documentation. As Quest hold a wholesale AFS licence, this report should not be passed on to any retail client.

The rating published on 10/2025 for the Quest Australian Equities Concentrated Portfolio is issued by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec Research). Ratings are general advice only and have been prepared without taking account of investors' objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec Research assumes no obligation to update. Lonsec Research uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2025 Lonsec. All rights reserved.